Merck Regimen to Reduce Nausea Meets Primary Endpoint
29 June 2015 - 11:27PM
Dow Jones News
By Chelsey Dulaney
Merck & Co. said Monday that its experimental drug regimen
to reduce nausea in patients receiving chemotherapy met its primary
endpoint goal in a late-stage study.
The phase-three study combined Merck's injectable fosaprepitant
dimeglumine, called Emend, with antivomiting medicines.
Merck said the regimen provided greater protection from nausea
and vomiting after chemotherapy than other antivomiting medicines
in the study. Side effects included fatigue and diarrhea.
Merck said it plans to submit its data to the Food and Drug
Administration in the second half of the year.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024